IFx-Hu2.0

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Q1 '27

HURAPhase 3$164M

IFx-Hu2.0 Phase 3 Est. Readout

IFx-Hu2.0• Advanced Or Metastatic Merkel Cell Carcinoma118

Q1 2027~QConfirmed

00%

Competitive Landscape

0 competitors in Advanced Or Metastatic Merkel Cell Carcinoma

Drug Information

Target Indication

Advanced Or Metastatic Merkel Cell Carcinoma

Clinical Trial

Last updated: 6/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

HURA

TuHURA Biosciences, Inc./NV

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts